Adherence Record — Keytruda (pembrolizumab)

AT RISK
Risk: HIGH (62/100)
Started: Oct 15, 2025
PDC: 68%
AI InsightsEngage InsightsActive
Overall Score
60
High
MEDIUM confidence
14 days ago
Insight Dimensions (2)
Engagement Risk Score
57Medium
Contributing Factors
• factors: ['moderate adherence', 'schedule conflicts']
Recommended Actions
→ Initiate proactive outreach
→ Adjust engagement strategy
Next Best Outreach Priority
60High
Contributing Factors
• Channel: Phone
• Action: benefits review
• factors: ['coverage renewal', 'call preferred']
Recommended Actions
→ Execute recommended outreach
→ Review channel preferences
Total Doses5Missed2Gap Days18
Open Barriers2Regimeninfusion / every 4 weeks
  1. Intervention: transportation assist
    planned
    Apr 15, 2026 — Arrange medical transportation service for infusion appointments.
  2. Intervention: side effect management
    in_progress
    Apr 8, 2026 — Coordinating with oncologist on anti-nausea pre-medication protocol.
  3. Gap: infusion delay
    high
    Apr 6, 2026 — 7 days | Severity: high | Open
  4. Barrier: side effects
    in_progress
    Mar 29, 2026 — Patient reports fatigue and nausea after infusions, considering discontinuation.
  5. Barrier: transportation
    open
    Mar 24, 2026 — Patient lacks reliable transportation to infusion center. Lives 45 minutes from ...
  6. Intervention: outreach call
    completed
    Mar 14, 2026 — Called patient to discuss importance of staying on therapy schedule. | Outcome: successful
  7. infusion — Keytruda (pembrolizumab)
    infusion
    Mar 9, 2026 — 7 days late
  8. Gap: infusion delay
    moderate
    Mar 2, 2026 — 7 days | Severity: moderate | Resolved
  9. infusion — Keytruda (pembrolizumab)
    infusion
    Feb 22, 2026 —
  10. infusion — Keytruda (pembrolizumab)
    infusion
    Jan 18, 2026 — 7 days late
  11. infusion — Keytruda (pembrolizumab)
    infusion
    Dec 14, 2025 —
  12. infusion — Keytruda (pembrolizumab)
    infusion
    Nov 14, 2025 —